In addition, our rosuvastatin-treated patients had significantly lower MPO level after 6 months compared to control group, and there was non-significant change in MPO level after 3 and 6 months compared to their baseline which is going with Andreou et al. results that reported that a short term treatment with low-dose rosuvastatin treatment significantly lowered MPO in heart failure patients [35]. The gene discussed is MPO; the disease is heart failure.